GLP-1受体激动剂妊娠期安全性的FAERS药物警戒分析
本研究基于FAERS数据库2004至2023年数据,分析15-55岁妊娠期暴露于GLP-1受体激动剂(GLP-1 RAs)的女性,共纳入354例、1671份不良反应报告。报告数自2012年起呈指数上升,中位年龄36岁,50.56%为高龄孕妇;失衡分析显示生殖系统(n=199)和胃肠系统(n=155)存在显著信号,自然流产和子痫前期最受关注。结论为妊娠期不推荐使用GLP-1 RAs,意外暴露时应密切监测母胎安全。
要点
- 妊娠期不推荐使用GLP-1 RAs,意外暴露需密切监测母胎安全。
- 生殖系统与胃肠系统ADR信号显著,自然流产和子痫前期最需关注。
- 除20-24岁组外多数年龄组风险升高,高龄孕妇占50.56%。
核心结论
- 妊娠期不推荐使用GLP-1 RAs;意外暴露时应密切监测以确保母胎安全。
- 研究识别出GLP-1 RAs在妊娠期潜在的生殖和胃肠系统不良反应信号。
研究设计与样本
- 基于FAERS数据库2004至2023年数据的药物警戒分析。
- 研究对象为15-55岁暴露于GLP-1 RAs的妊娠女性,共354例、1671份ADR报告。
- 采用描述性分析及报告比值比和贝叶斯置信传播神经网络进行失衡分析以检测ADR信号。
主要发现
- 报告病例自2012年起呈指数上升,中位年龄36岁,50.56%为高龄孕妇。
- 失衡分析显示生殖系统(n=199)和胃肠系统(n=155)存在显著ADR信号。
- 自然流产和子痫前期是最受关注的不良反应。
- 未发现显著的剂量相关差异;除20-24岁组外,多数年龄组风险升高。
临床怎么用
- 临床应避免在妊娠期处方GLP-1 RAs。
- 对意外暴露于GLP-1 RAs的孕妇应密切监测母胎安全。
- 用药决策时应关注生殖系统和胃肠系统不良反应信号,尤其自然流产和子痫前期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The use of (GLP-1 RAs) among pregnant women is escalating, yet safety data remain insufficient. This study aims to comprehensively assess adverse drug reactions (ADRs) associated with GLP-1 RAs in pregnant women using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. METHODS: FAERS data from 2004 to 2023 were analysed, focusing on pregnant women aged 15-55 years exposed to GLP-1 RAs. Descriptive analysis covered patient demographics, clinical aspects and annual trends. Disproportionality analysis used reporting odds ratio and Bayesian confidence propagation neural network to detect ADR signals. RESULTS: Among 354 cases with 1671 ADR reports, an exponential rise in reported cases since 2012 was observed. The median age of the affected women was 36 years, with 50.56% classified as advanced age pregnant. The disproportionality analysis revealed significant ADR signals in the reproductive (n = 199) and gastrointestinal systems (n = 155), with spontaneous abortion and pre-eclampsia being the most concerning. Additionally, while no significant dose-related differences were found, the age subgroup analysis indicated heightened risk across most age groups, except for those aged 20-24 years, highlighting the need for careful monitoring of GLP-1 RAs used during pregnancy. CONCLUSION: This study highlights increasing GLP-1 RA use in pregnant women and identifies potential pregnant ADRs. GLP-1 RAs are not recommended for use during pregnancy. In cases of unintentional exposure, close monitoring is advised to ensure maternal and foetal safety. These findings provide valuable insights for clinicians making informed decisions and regulators considering using GLP-1 RA in pregnancy.
引用
- Zhou J, Wei Z, Lai W, et al. The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System. Br J Clin Pharmacol. 2024. PMID: 39658840. doi:10.1111/bcp.16354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。